Fig 1: Inter-laboratory anti-FGFR3 ELISA validation and DRG binding. (A) Mean OD440 for the n = 42 sera included in the inter-laboratory comparison are higher in center 1 than center 2. Respective threshold values are marked in red. (B) Mean ODs correlate between the two centers. Regression line is shown as solid and 95% confidence bands as dashed lines. (C) Concordance of the overall positive/negative testing results for both centers is displayed in percentage with bar graphs. (D) No specific binding of a healthy control serum without FGFR3 antibodies to DRG sections (shown in yellow). Commercial anti-FGFR3 is shown in cyan and anti-peripherin in magenta, without serum colocalization. (E) IgG binding of an anti-FGFR3 positive serum of a patient with SFN to DRG sections. Arrowhead marks cytosol of small DRG neurons and membrane specifically bound by patient IgG. Colocalization with commercial anti-FGFR3 and anti-peripherin appears white. Scale bar = 50 µm. DRG, Dorsal Root Ganglion; FGFR3, Fibroblast Growth Factor Receptor 3; OD, optical density; SFN, Small Fiber Neuropathy. ***, p < 0.001.
Fig 2: Schematic illustration of the study design. DRG, Dorsal Root Ganglion; FGFR3, Fibroblast Growth Factor Receptor 3; FMS, Fibromyalgia Syndrome; HC, healthy controls; pat., patients; SFN, Small Fiber Neuropathy; SNN, Sensory Neuronopathy.
Supplier Page from Thermo Fisher Scientific for Recombinant Human FGFR3, His Tag Protein